← back to search

Pauline Harper

Karolinska University Hospital · SE
Area of research
Molecular Biology · Rheumatology
Research interest
Research interests include Porphyrin Metabolism and Disorders, Heme Oxygenase-1 and Carbon Monoxide, Folate and B Vitamins Research, and Neonatal Health and Biochemistry.
h-index
37
citations
4,900
works
140
NIH funding
primary concept
Medicine
email

Recent publications

New cases of δ-aminolevulinic acid dehydratase deficiency: Functional insights into gene variants using an innovative mouse liver model.
2026cited by 1position: contributordoi
Clinical Characteristics and Outcomes of Acute Intermittent Porphyria: Insights From the European Porphyria Registry.
2026cited by 0position: contributordoi
Persistent Beetroot Colored Urine in a Three-Year-Old Child: A Case Report.
2025cited by 0position: contributordoi
Hepatocellular Carcinoma in Acute Porphyria: Incidence and Risk Factors.
2025cited by 0position: contributordoi
From chemistry to genomics: A concise history of the porphyrias.
2024cited by 3position: contributordoi
Key terms and definitions in acute porphyrias: Results of an international Delphi consensus led by the European porphyria network.
2023cited by 29position: contributordoi
Risk for incident comorbidities, nonhepatic cancer and mortality in acute hepatic porphyria: A matched cohort study in 1244 individuals.
2023cited by 10position: contributordoi
Porphyrin precursors and risk of primary liver cancer in acute intermittent porphyria: A case-control study of 188 patients.
2023cited by 5position: contributordoi
Comment on Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. <i>Cancers</i> 2022, <i>14</i>, 2947.
2023cited by 1position: contributordoi
Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals
Journal of Internal Medicine 2022cited by 59position: middledoi
Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals.
2022cited by 42position: contributordoi
RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
2022cited by 19position: contributordoi
A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
2021cited by 24position: contributordoi
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
New England Journal of Medicine 2020cited by 587position: middledoi
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
2020cited by 428position: contributordoi
EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks.
2020cited by 123position: contributordoi
Challenges in the management of acute intermittent porphyria with recurrent attacks during pregnancy: A case report.
2020cited by 5position: contributordoi
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
New England Journal of Medicine 2019cited by 254position: middledoi
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
2019cited by 196position: contributordoi
EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks
Hepatology 2019cited by 169position: middledoi
International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias.
2019cited by 17position: contributordoi
Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver
Journal of Internal Medicine 2018cited by 119position: middledoi
Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria
Journal of Hepatology 2016cited by 142position: middledoi
High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria
Journal of Inherited Metabolic Disease 2013cited by 76position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Paolo Ventura · University of Parma5 papers (2020–2026)David C. Rees · King's College Hospital4 papers (2019–2020) · 4 papers (2023–2026)Eliane Sardh · Karolinska University Hospital3 papers (2013–2022)Karl E. Anderson · Moderna Therapeutics (United States)3 papers (2019–2019)Janneke G. Langendonk · Erasmus MC3 papers (2020–2026) · 3 papers (2022–2023)Mattias Lissing · BMJ Publishing Group3 papers (2022–2023)Daphne Vassiliou · Karolinska Institutet2 papers (2019–2022)Manisha Balwani · University of Miami2 papers (2019–2020)Staffan Wåhlin · Karolinska University Hospital2 papers (2013–2022)Elena Di Pierro · University of Milan2 papers (2026–2026) · 2 papers (2023–2023)Hannes Hagström · Stockholm South General Hospital2 papers (2022–2023) · 2 papers (2023–2023)Penelope E. Stein · King's College Hospital2 papers (2019–2023)Gloria González‐Aseguinolaza · Gene Therapy Laboratory1 papers (2016–2016)Matías A. Ávila · Instituto de Salud Carlos III1 papers (2026–2026) · 1 papers (2019–2019)Ylva Flodérus · Karolinska University Hospital1 papers (2022–2022)